CSIMarket
 

Tilray Brands Inc   (NASDAQ: TLRY)

Tilray Brands Inc 's

Competitiveness




 

TLRY Sales vs. its Competitors Q3 2026



Comparing the current results to its competitors, Tilray Brands Inc reported Revenue increase in the 3 quarter 2026 by 11.32 % year on year.
The sales growth was above Tilray Brands Inc 's competitors' average revenue growth of 10.16 %, achieved in the same quarter.

List of TLRY Competitors





Revenue Growth Comparisons




Net Income Comparison


Tilray Brands Inc recorded a net loss, as well as most of its competitors.

<<  TLRY Stock Performance Comparisons


Tilray Brands Inc 's Comment on Competition and Industry Peers


The company operates in the U.S. beverage market within the craft beer and spirits industries, as well as the broader beverage alcohol sector, which includes domestic and imported beers, flavored alcoholic beverages, spirits, hard ciders, ready-to-drink beverages, fermented malt-based beverages, and hard seltzers. It faces significant competition from numerous participants across these segments. Its products are not primary brands in distributors' portfolios, requiring competition for distributor attention and sales efforts. Consumer trends such as reduced alcohol consumption due to economic pressures, GLP-1 drug use, and wellness concerns affect demand. In the U.K., the company competes in a highly competitive beer market comprising international brewers, national brewers, regional brewers, and independent craft brewers. The U.K. beverage industry experiences cost pressures from inflation, higher input costs, labor expenses, and changing consumer spending patterns, increasing competition in retail and hospitality channels. The company operates in the U.K. market through BrewDog's brand portfolio, bar network, retail presence, and e-commerce platform. In the cannabis segment, the company was among the first authorized to cultivate and sell legal medical cannabis and has supplied products to patients in over 20 countries via subsidiaries and pharmaceutical distributors. Competitors identified include BrewDog and Tilray Medical.



  

Overall company Market Share Q3 2026

Company's competitiveness improved within Overall company, with revenue growth of 11.32 %, faster than company's peers within this division.
<<  More on TLRY Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Tilray Brands Inc




Kaya Holdings Inc
Share Performance



0.00%
This Quarter



Kaya Holdings Inc
Profile

Kaya Holdings Inc's business model revolves around operating and franchising legal cannabis retail stores under the Smoke Shop brand. Their focus is on offering a diverse range of cannabis products, accessories, and services to cater to the needs of consumers in states where marijuana is legalized.

More about Kaya Holdings Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ -0.001 mill. $ -11.857 mill.


Quantum Biopharma Ltd
Share Performance



-90.01%
This Year



Quantum Biopharma Ltd
Profile

Fsd Pharma Inc's business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.

More about Quantum Biopharma Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -37.457 mill.


Igc Pharma Inc
Share Performance



+3.45%
This Year



Igc Pharma Inc
Profile

Igc Pharma Inc's business model revolves around the development and commercialization of innovative therapeutics derived from cannabis-based compounds. The company focuses on researching treatments for indications such as epilepsy, pain, and inflammation. Igc Pharma Inc primarily operates in the pharmaceutical industry, aiming to provide safe and effective alternatives to conventional medicines.

More about Igc Pharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 30.099 mill. $ 1.101 mill. $ -8.758 mill.


Intercure Ltd
Share Performance



+421.15%
This Quarter



Intercure Ltd
Profile

Intercure Ltd is a company that operates in the healthcare sector. Their business model focuses on providing innovative medical solutions and technologies to improve patient outcomes and quality of life. They likely collaborate with healthcare providers, research institutions, and pharmaceutical companies to develop and market their products.

More about Intercure Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 270.200 mill. $ -36.784 mill.


Incannex Healthcare Inc
Share Performance



+6.05%
This Quarter



Incannex Healthcare Inc
Profile

Incannex Heal is developing drug candidates including IHL-42X, PSX-001, and IHL-675A.

More about Incannex Healthcare Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 40.071 mill. $ - mill. $ -19.279 mill.

16 more competitors available

Sign in to see all competitors

Sources: Tilray Brands Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tilray Brands Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.